<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="46">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539262</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-553-9020</org_study_id>
    <nct_id>NCT04539262</nct_id>
  </id_info>
  <brief_title>Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation</brief_title>
  <official_title>A Phase 1b/2a Study in Participants With Early Stage COVID-19 to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to characterize the impact of inhaled remdesivir (RDV)&#xD;
      on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load in participants&#xD;
      with early stage coronavirus disease 2019 (COVID-19).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will have multiple parts: Part A, Part B, and Part C. Part B will be conducted if&#xD;
      supported by evaluation in healthy volunteers in another Phase 1a Gilead study&#xD;
      (GS-US-553-9018). Participants in Part C will be enrolled after review of preliminary safety&#xD;
      and available efficacy data from Parts A and B through at least Day 7.&#xD;
&#xD;
      GS-US-553-9018 is a Phase 1a randomized, blinded, placebo-controlled, single- and&#xD;
      multiple-dose study in healthy volunteers to evaluate the safety, tolerability, and&#xD;
      pharmacokinetics of remdesivir administered by inhalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2020</start_date>
  <completion_date type="Actual">March 22, 2021</completion_date>
  <primary_completion_date type="Actual">February 26, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
    <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</measure>
    <time_frame>First dose date up to 5 days plus 30 days</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade</measure>
    <time_frame>First dose date up to 5 days plus 30 days</time_frame>
    <description>Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation</measure>
    <time_frame>First dose date up to 5 days plus 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28</measure>
    <time_frame>Randomization up to Day 28</time_frame>
    <description>The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With COVID-19 Related MAVs or Death by Day 28</measure>
    <time_frame>Randomization up to Day 28</time_frame>
    <description>The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Hospitalization by Day 28</measure>
    <time_frame>Day 1 up to Day 28</time_frame>
    <description>The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where &quot;Dose&quot; is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</measure>
    <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
    <description>Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</measure>
    <time_frame>Baseline, Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</measure>
    <time_frame>Baseline, Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5</measure>
    <time_frame>Baseline, Day 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7</measure>
    <time_frame>Baseline, Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</measure>
    <time_frame>Baseline, Day 14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</measure>
    <time_frame>Baseline up to Day 17</time_frame>
    <description>The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</measure>
    <time_frame>Baseline up to Day 17</time_frame>
    <description>The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)</measure>
    <time_frame>Baseline up to Day 17</time_frame>
    <description>The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C</measure>
    <time_frame>First dose date up to Day 14</time_frame>
    <description>The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">156</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Remdesivir (RDV), Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RDV 31 mg administered daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDV + Placebo, Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RDV 31 mg administered daily for 3 days followed by placebo to match RDV daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match inhaled RDV in Part A daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDV, Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RDV 62 mg administered daily for up to 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDV + Placebo, Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RDV 62 mg administered daily for up to 3 days followed by placebo to match RDV daily for 2 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match inhaled RDV in Part B daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RDV, Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive inhaled RDV 39 mg administered daily for 5 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Part C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive placebo to match inhaled RDV in Part C daily for 5 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remdesivir (RDV)</intervention_name>
    <description>Administered as an aerosolized solution</description>
    <arm_group_label>RDV + Placebo, Part A</arm_group_label>
    <arm_group_label>RDV + Placebo, Part B</arm_group_label>
    <arm_group_label>RDV, Part B</arm_group_label>
    <arm_group_label>RDV, Part C</arm_group_label>
    <arm_group_label>Remdesivir (RDV), Part A</arm_group_label>
    <other_name>GS-5734™</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered as an aerosolized solution</description>
    <arm_group_label>Placebo, Part A</arm_group_label>
    <arm_group_label>Placebo, Part B</arm_group_label>
    <arm_group_label>Placebo, Part C</arm_group_label>
    <arm_group_label>RDV + Placebo, Part A</arm_group_label>
    <arm_group_label>RDV + Placebo, Part B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Willing and able to provide written informed consent, or with a legal representative&#xD;
             who can provide informed consent&#xD;
&#xD;
          -  SARS-CoV-2 infection first confirmed by polymerase chain reaction (PCR) (Parts A and&#xD;
             B) or by nucleic acid testing or direct antigen testing (Part C) with sample collected&#xD;
             ≤ 4 days prior to randomization&#xD;
&#xD;
          -  COVID-19 symptom onset ≤ 7 days prior to randomization&#xD;
&#xD;
          -  Oxygen saturation as measured by pulse oximetry (SpO2) &gt; 94% on room air&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Ongoing or prior participation in any other clinical trial of an experimental vaccine&#xD;
             or treatment for COVID-19&#xD;
&#xD;
          -  Prior or current hospitalization for COVID-19 or need for hospitalization&#xD;
&#xD;
          -  Treatment of COVID-19 with other agents with actual or possible direct antiviral&#xD;
             activity against SARS-CoV-2 including intravenous (IV) RDV or administration of any&#xD;
             SARS-CoV-2 (or COVID-19) vaccine&#xD;
&#xD;
               -  Participants chronically administered chloroquine or hydroxychloroquine for any&#xD;
                  reason are to be excluded&#xD;
&#xD;
          -  Requiring oxygen supplementation&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Breastfeeding female&#xD;
&#xD;
          -  Known hypersensitivity to the study treatment, its metabolites, or formulation&#xD;
             excipient&#xD;
&#xD;
          -  Pre-existing pulmonary conditions such as chronic obstructive pulmonary disease or&#xD;
             asthma (Parts A and B only)&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Institute for Liver Health</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Institute for Liver Health</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franco Felizarta, MD</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora FDRC Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>92627</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Elevated Health</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Clinical Research</name>
      <address>
        <city>Placentia</city>
        <state>California</state>
        <zip>92870</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC Davis Health/Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bradenton Research Center, Inc.</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integrity Clinical Research, LLC</name>
      <address>
        <city>Doral</city>
        <state>Florida</state>
        <zip>33166</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Cross Hospital</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evolution Clinical Trials, Inc.</name>
      <address>
        <city>Hialeah Gardens</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research in Miami, Inc.</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optimus U Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>L &amp; C Professional Medical Research Institute</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westchester Research Center at Westchester General Hospital</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33155</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedBio Trials</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nuovida Research Center, Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IMIC Inc</name>
      <address>
        <city>Palmetto Bay</city>
        <state>Florida</state>
        <zip>33157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, PA</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Care Research</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CTU Covid Research Center</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research</name>
      <address>
        <city>Vandalia</city>
        <state>Ohio</state>
        <zip>45066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inquest Clinical Research</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DFW Clinical Research</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PCP for Life-Tidwell</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Regional Medical Center Everett</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>August 26, 2020</study_first_submitted>
  <study_first_submitted_qc>September 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2020</study_first_posted>
  <results_first_submitted>February 18, 2022</results_first_submitted>
  <results_first_submitted_qc>February 18, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2022</results_first_posted>
  <last_update_submitted>February 18, 2022</last_update_submitted>
  <last_update_submitted_qc>February 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remdesivir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 13, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT04539262/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 4, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT04539262/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study sites in the United States. The first participant was screened on 14 September 2020. The last study visit occurred on 22 March 2021.</recruitment_details>
      <pre_assignment_details>168 participants were screened.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Remdesivir (RDV), Part A</title>
          <description>Participants received inhaled remdesivir (RDV) 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>RDV + Placebo, Part A</title>
          <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="P3">
          <title>Placebo, Part A</title>
          <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
        </group>
        <group group_id="P4">
          <title>RDV, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="P5">
          <title>RDV + Placebo, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="P6">
          <title>Placebo, Part B</title>
          <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
        </group>
        <group group_id="P7">
          <title>RDV, Part C</title>
          <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
        </group>
        <group group_id="P8">
          <title>Placebo, Part C</title>
          <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="62"/>
                <participants group_id="P8" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="13"/>
                <participants group_id="P7" count="61"/>
                <participants group_id="P8" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized, Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>RDV, Part A</title>
          <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>RDV + Placebo, Part A</title>
          <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="B3">
          <title>Placebo, Part A</title>
          <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
        </group>
        <group group_id="B4">
          <title>RDV, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="B5">
          <title>RDV + Placebo, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="B6">
          <title>Placebo, Part B</title>
          <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
        </group>
        <group group_id="B7">
          <title>RDV, Part C</title>
          <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
        </group>
        <group group_id="B8">
          <title>Placebo, Part C</title>
          <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
        </group>
        <group group_id="B9">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="12"/>
            <count group_id="B5" value="12"/>
            <count group_id="B6" value="13"/>
            <count group_id="B7" value="61"/>
            <count group_id="B8" value="20"/>
            <count group_id="B9" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt; 60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="61"/>
                    <count group_id="B8" value="20"/>
                    <count group_id="B9" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="55"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥ 60 years</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="61"/>
                    <count group_id="B8" value="20"/>
                    <count group_id="B9" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="61"/>
                    <count group_id="B8" value="20"/>
                    <count group_id="B9" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="34"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="77"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="12"/>
                    <measurement group_id="B9" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="61"/>
                    <count group_id="B8" value="20"/>
                    <count group_id="B9" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="40"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="21"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="74"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Not Permitted means local regulators did not allow collection of race information.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="12"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="12"/>
                    <count group_id="B5" value="12"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="61"/>
                    <count group_id="B8" value="20"/>
                    <count group_id="B9" value="154"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="47"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="126"/>
                  </measurement_list>
                </category>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Permitted</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SARS-CoV-2 Viral load - Nasopharyngeal</title>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="12"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="10"/>
                    <count group_id="B5" value="10"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="18"/>
                    <count group_id="B9" value="143"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.29" spread="1.901"/>
                    <measurement group_id="B2" value="6.56" spread="1.065"/>
                    <measurement group_id="B3" value="6.81" spread="1.065"/>
                    <measurement group_id="B4" value="5.23" spread="1.980"/>
                    <measurement group_id="B5" value="6.41" spread="1.883"/>
                    <measurement group_id="B6" value="7.09" spread="1.288"/>
                    <measurement group_id="B7" value="5.69" spread="2.004"/>
                    <measurement group_id="B8" value="5.76" spread="1.839"/>
                    <measurement group_id="B9" value="6.14" spread="1.859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SARS-CoV-2 Viral load - Oropharyngeal</title>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="11"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="12"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="10"/>
                    <count group_id="B6" value="12"/>
                    <count group_id="B7" value="57"/>
                    <count group_id="B8" value="18"/>
                    <count group_id="B9" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.69" spread="0.959"/>
                    <measurement group_id="B2" value="4.74" spread="1.225"/>
                    <measurement group_id="B3" value="5.57" spread="1.275"/>
                    <measurement group_id="B4" value="4.40" spread="1.772"/>
                    <measurement group_id="B5" value="5.16" spread="1.356"/>
                    <measurement group_id="B6" value="4.79" spread="1.377"/>
                    <measurement group_id="B7" value="4.38" spread="1.610"/>
                    <measurement group_id="B8" value="3.94" spread="1.203"/>
                    <measurement group_id="B9" value="4.64" spread="1.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>SARS-CoV-2 Viral load - Saliva</title>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="10"/>
                    <count group_id="B2" value="11"/>
                    <count group_id="B3" value="9"/>
                    <count group_id="B4" value="11"/>
                    <count group_id="B5" value="10"/>
                    <count group_id="B6" value="13"/>
                    <count group_id="B7" value="59"/>
                    <count group_id="B8" value="19"/>
                    <count group_id="B9" value="142"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.56" spread="1.682"/>
                    <measurement group_id="B2" value="5.19" spread="1.312"/>
                    <measurement group_id="B3" value="4.77" spread="1.218"/>
                    <measurement group_id="B4" value="5.15" spread="2.048"/>
                    <measurement group_id="B5" value="4.77" spread="1.281"/>
                    <measurement group_id="B6" value="5.60" spread="1.074"/>
                    <measurement group_id="B7" value="4.93" spread="1.785"/>
                    <measurement group_id="B8" value="4.57" spread="1.559"/>
                    <measurement group_id="B9" value="5.00" spread="1.613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7</title>
        <description>Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the Nasopharyngeal Modified Full Analysis Set (mFAS) (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using nasopharyngeal swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Average Change From Baseline in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load Through Day 7</title>
          <description>Time-weighted average change in SARS-CoV-2 viral load was defined as area under the concentration versus time curve (AUC) of viral load change divided by time between baseline through Day 7.</description>
          <population>Participants in the Nasopharyngeal Modified Full Analysis Set (mFAS) (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using nasopharyngeal swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.04" spread="0.999"/>
                    <measurement group_id="O2" value="-1.51" spread="0.812"/>
                    <measurement group_id="O3" value="-1.24" spread="0.961"/>
                    <measurement group_id="O4" value="-1.21" spread="1.108"/>
                    <measurement group_id="O5" value="-1.42" spread="0.975"/>
                    <measurement group_id="O6" value="-1.40" spread="0.796"/>
                    <measurement group_id="O7" value="-1.91" spread="1.186"/>
                    <measurement group_id="O8" value="-1.93" spread="1.284"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1117</p_value>
            <p_value_desc>Least square (LS) Mean, Standard Error (SE), 95% CI and p-value were from Analysis of covariance (ANCOVA) with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Square Mean Difference by Day 7</param_type>
            <param_value>-0.66</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.49</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3793</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.16</ci_lower_limit>
            <ci_upper_limit>0.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5248</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.24</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.00</ci_lower_limit>
            <ci_upper_limit>0.52</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4610</p_value>
            <method>ANCOVA</method>
            <method_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate</method_desc>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.25</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5006</p_value>
            <p_value_desc>LS Mean (SE), 95% CI and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.20</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.30</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7</title>
        <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the Oropharyngeal mFAS (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using oropharyngeal swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Average Change From Baseline in Oropharyngeal SARS-CoV-2 Viral Load Through Day 7</title>
          <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
          <population>Participants in the Oropharyngeal mFAS (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using oropharyngeal swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.856"/>
                    <measurement group_id="O2" value="-0.55" spread="0.868"/>
                    <measurement group_id="O3" value="-1.39" spread="1.036"/>
                    <measurement group_id="O4" value="-1.14" spread="1.133"/>
                    <measurement group_id="O5" value="-0.85" spread="1.164"/>
                    <measurement group_id="O6" value="-0.70" spread="0.902"/>
                    <measurement group_id="O7" value="-0.83" spread="1.073"/>
                    <measurement group_id="O8" value="-0.46" spread="1.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3417</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.33</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.34</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>1.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1803</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.49</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1233</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.55</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.27</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8203</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.08</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.35</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6458</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.65</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7</title>
        <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the saliva mFAS (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using saliva swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time-weighted Average Change From Baseline in Saliva SARS-CoV-2 Viral Load Through Day 7</title>
          <description>Time-weighted average change in SARS-CoV-2 viral load was defined as AUC of viral load change divided by time between baseline through Day 7.</description>
          <population>Participants in the saliva mFAS (all participants who were randomized into the study, had received at least 1 dose of study treatment and had positive SARS-CoV-2 viral load using saliva swab sample at baseline [the result of 'No SARS-CoV-2 detected' was considered as negative]) with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="44"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.80" spread="0.469"/>
                    <measurement group_id="O2" value="-1.27" spread="0.877"/>
                    <measurement group_id="O3" value="-0.49" spread="1.148"/>
                    <measurement group_id="O4" value="-1.09" spread="1.497"/>
                    <measurement group_id="O5" value="-0.61" spread="0.676"/>
                    <measurement group_id="O6" value="-0.93" spread="0.678"/>
                    <measurement group_id="O7" value="-1.25" spread="0.977"/>
                    <measurement group_id="O8" value="-1.01" spread="1.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5951</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.05</ci_lower_limit>
            <ci_upper_limit>0.61</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</non_inferiority_desc>
            <p_value>0.0872</p_value>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.71</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.54</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6031</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>-0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.94</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.7578</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.12</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8846</p_value>
            <p_value_desc>LS Mean (SE), 95% CI, and p-value were from ANCOVA with baseline viral load as a covariate.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>LS Mean Difference by Day 7</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.26</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.</description>
        <time_frame>First dose date up to 5 days plus 30 days</time_frame>
        <population>The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment Emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a participant administered a study drug, which did not necessarily have a causal relationship with the treatment. AE was therefore any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of the study drug, whether or not considered related to the study drug. TEAEs: AE with an onset date on or after the study drug start date and no later than 30 days after study drug stop date; or any AE leading to study drug discontinuation.</description>
          <population>The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="58.3"/>
                    <measurement group_id="O3" value="41.7"/>
                    <measurement group_id="O4" value="33.3"/>
                    <measurement group_id="O5" value="58.3"/>
                    <measurement group_id="O6" value="38.5"/>
                    <measurement group_id="O7" value="42.6"/>
                    <measurement group_id="O8" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade</title>
        <description>Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.</description>
        <time_frame>First dose date up to 5 days plus 30 days</time_frame>
        <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Laboratory Abnormalities as Per Severity Grade</title>
          <description>Treatment-emergent laboratory abnormalities were graded using the Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.1 July 2017. Laboratory abnormalities were graded as Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening). Percentage of participants with any severity grade were reported.</description>
          <population>Participants in the Safety Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="11"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.3"/>
                    <measurement group_id="O2" value="91.7"/>
                    <measurement group_id="O3" value="63.6"/>
                    <measurement group_id="O4" value="63.6"/>
                    <measurement group_id="O5" value="83.3"/>
                    <measurement group_id="O6" value="61.5"/>
                    <measurement group_id="O7" value="68.9"/>
                    <measurement group_id="O8" value="75.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation</title>
        <time_frame>First dose date up to 5 days plus 30 days</time_frame>
        <population>Participants in the Safety Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Treatment-Emergent Adverse Events Leading to Study Treatment Discontinuation</title>
          <population>Participants in the Safety Analysis Set were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1.6"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28</title>
        <description>The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
        <time_frame>Randomization up to Day 28</time_frame>
        <population>Participants in the Full Analysis Set (all participants who were randomized into the study, and had received at least 1 dose of study treatment) were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-Cause Medically Attended Visits (MAVs) or Death by Day 28</title>
          <description>The composite outcome of all-cause MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
          <population>Participants in the Full Analysis Set (all participants who were randomized into the study, and had received at least 1 dose of study treatment) were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With COVID-19 Related MAVs or Death by Day 28</title>
        <description>The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
        <time_frame>Randomization up to Day 28</time_frame>
        <population>Participants in the Full Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With COVID-19 Related MAVs or Death by Day 28</title>
          <description>The composite outcome of COVID-19 related MAVs (medical visits attended in person by the participant and a health care professional) or all-cause death by Study Day 28 were estimated using Kaplan-Meier methods by treatment group.</description>
          <population>Participants in the Full Analysis Set were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Hospitalization by Day 28</title>
        <description>The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.</description>
        <time_frame>Day 1 up to Day 28</time_frame>
        <population>Participants in the Full Analysis Set were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Hospitalization by Day 28</title>
          <description>The composite of all-cause hospitalization was estimated using Kaplan-Meier methods by treatment group.</description>
          <population>Participants in the Full Analysis Set were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="12"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="61"/>
                <count group_id="O8" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic (PK) Parameter: AUC0-24h of Remdesivir (RDV) and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>AUC0-24h was defined as the concentration of drug over time between time 0 to time 24 hours. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUClast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>AUClast was defined as the concentration of drug from time zero to the last observable concentration.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where &quot;Dose&quot; is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: CLss/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>CLss/F was defined as apparent oral clearance at steady state after administration of the drug. CLss/F = Dose/AUCtau, where &quot;Dose&quot; is the dose of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: t1/2 of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>t1/2 was defined as the estimate of the terminal elimination half-life of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Vz/F of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Vz/F was defined as the apparent volume of distribution of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Cmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Cmax was defined as the maximum observed concentration of drug.Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered as an aerosolized solution by inhalation through facemask daily for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tmax of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Tmax was defined as the time (observed time point) of Cmax. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Clast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Clast was defined as the last observable concentration of drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Tlast of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Tlast was defined as the time (observed time point) of Clast. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: AUCtau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>AUCtau is defined as concentration of drug over time (the area under the concentration versus time curve over the dosing interval). Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: λz of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>λz was defined as the terminal elimination rate constant, estimated by linear regression of the terminal elimination phase of the log plasma concentration of drug versus time curve of the drug. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
        <description>Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
        <time_frame>Sparse PK: Day 1 (end of nebulization) and Day 3 (predose and end of nebulization); Intensive PK: Day 1 and Day 3 or Day 5 (0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization); Nebulization duration: 17-34 minutes.</time_frame>
        <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK Parameter: Ctau of RDV and Its Metabolites (GS-441524 and GS-704277) in Parts A and B</title>
          <description>Ctau was defined as the observed drug concentration at the end of the dosing interval. Time Frame for PK samples: Sparse PK (all participants): Day 1 (end of nebulization, and optional 2-hour post nebulization), and Day 3 (predose and end of nebulization); Intensive PK (Up to 6 participants/group in Part A &amp; Part B): Day 1 and an additional sample at Day 3 or Day 5 at the following time points: 0 (predose), 0.25, 0.5, 0.75, 1, 1.5, 2, 4, and 24 hours post end of nebulization.</description>
          <population>As only 1 participant was evaluated, results for PK parameters were not reported for the protection of personal data and to avoid re-identification.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</title>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</title>
          <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.44" spread="1.240"/>
                    <measurement group_id="O2" value="-1.67" spread="0.992"/>
                    <measurement group_id="O3" value="-1.78" spread="1.357"/>
                    <measurement group_id="O4" value="-1.53" spread="1.063"/>
                    <measurement group_id="O5" value="-1.68" spread="1.475"/>
                    <measurement group_id="O6" value="-2.09" spread="1.052"/>
                    <measurement group_id="O7" value="-2.01" spread="1.402"/>
                    <measurement group_id="O8" value="-2.06" spread="1.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</title>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 5</title>
          <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="40"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.24" spread="0.957"/>
                    <measurement group_id="O2" value="-0.88" spread="0.839"/>
                    <measurement group_id="O3" value="-1.26" spread="1.418"/>
                    <measurement group_id="O4" value="-1.29" spread="1.457"/>
                    <measurement group_id="O5" value="-1.13" spread="1.394"/>
                    <measurement group_id="O6" value="-1.10" spread="0.988"/>
                    <measurement group_id="O7" value="-0.92" spread="1.213"/>
                    <measurement group_id="O8" value="-0.66" spread="1.581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5</title>
        <time_frame>Baseline, Day 5</time_frame>
        <population>Participants in the Saliva mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 5</title>
          <population>Participants in the Saliva mFAS with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="42"/>
                <count group_id="O8" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.99" spread="0.562"/>
                    <measurement group_id="O2" value="-1.26" spread="1.288"/>
                    <measurement group_id="O3" value="-0.77" spread="1.449"/>
                    <measurement group_id="O4" value="-1.60" spread="1.443"/>
                    <measurement group_id="O5" value="-0.31" spread="0.708"/>
                    <measurement group_id="O6" value="-0.92" spread="1.040"/>
                    <measurement group_id="O7" value="-1.36" spread="1.056"/>
                    <measurement group_id="O8" value="-1.15" spread="0.962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</title>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</title>
          <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="10"/>
                <count group_id="O7" value="39"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.05" spread="1.225"/>
                    <measurement group_id="O2" value="-2.12" spread="1.051"/>
                    <measurement group_id="O3" value="-2.09" spread="1.331"/>
                    <measurement group_id="O4" value="-1.80" spread="1.389"/>
                    <measurement group_id="O5" value="-2.30" spread="1.257"/>
                    <measurement group_id="O6" value="-2.34" spread="1.873"/>
                    <measurement group_id="O7" value="-2.64" spread="1.299"/>
                    <measurement group_id="O8" value="-2.62" spread="1.555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</title>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 7</title>
          <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
          <units>log10copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.76" spread="1.113"/>
                    <measurement group_id="O2" value="-0.40" spread="1.049"/>
                    <measurement group_id="O3" value="-1.98" spread="0.971"/>
                    <measurement group_id="O4" value="-1.73" spread="1.513"/>
                    <measurement group_id="O5" value="-1.08" spread="1.160"/>
                    <measurement group_id="O6" value="-1.27" spread="0.845"/>
                    <measurement group_id="O7" value="-1.07" spread="1.122"/>
                    <measurement group_id="O8" value="-0.62" spread="1.606"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7</title>
        <time_frame>Baseline, Day 7</time_frame>
        <population>Participants in the Saliva mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 7</title>
          <population>Participants in the Saliva mFAS with available data were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="38"/>
                <count group_id="O8" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.28" spread="1.102"/>
                    <measurement group_id="O2" value="-1.24" spread="2.108"/>
                    <measurement group_id="O3" value="-0.62" spread="1.406"/>
                    <measurement group_id="O4" value="-1.91" spread="1.667"/>
                    <measurement group_id="O5" value="-0.99" spread="0.943"/>
                    <measurement group_id="O6" value="-1.53" spread="1.553"/>
                    <measurement group_id="O7" value="-1.69" spread="1.302"/>
                    <measurement group_id="O8" value="-1.31" spread="1.752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
        <time_frame>Baseline, Day 14</time_frame>
        <population>Participants in the Nasopharyngeal mFAS with available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Nasopharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
          <population>Participants in the Nasopharyngeal mFAS with available were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.11" spread="1.304"/>
                    <measurement group_id="O2" value="-2.96" spread="1.475"/>
                    <measurement group_id="O3" value="-3.31" spread="1.198"/>
                    <measurement group_id="O4" value="-2.82" spread="1.888"/>
                    <measurement group_id="O5" value="-2.86" spread="1.837"/>
                    <measurement group_id="O6" value="-3.41" spread="1.442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
        <time_frame>Baseline, Day 14</time_frame>
        <population>Participants in the Oropharyngeal mFAS with available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Oropharyngeal SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
          <population>Participants in the Oropharyngeal mFAS with available were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.46" spread="0.908"/>
                    <measurement group_id="O2" value="-1.47" spread="0.841"/>
                    <measurement group_id="O3" value="-2.36" spread="0.951"/>
                    <measurement group_id="O4" value="-1.46" spread="1.194"/>
                    <measurement group_id="O5" value="-1.95" spread="1.283"/>
                    <measurement group_id="O6" value="-2.05" spread="1.092"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
        <time_frame>Baseline, Day 14</time_frame>
        <population>Participants in the Saliva mFAS with available were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Saliva SARS-CoV-2 Viral Load From Baseline to Day 14 in Parts A and B</title>
          <population>Participants in the Saliva mFAS with available were analyzed.</population>
          <units>log10 copies/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.58" spread="1.413"/>
                    <measurement group_id="O2" value="-2.27" spread="1.136"/>
                    <measurement group_id="O3" value="-1.78" spread="0.618"/>
                    <measurement group_id="O4" value="-2.30" spread="1.505"/>
                    <measurement group_id="O5" value="-2.11" spread="1.171"/>
                    <measurement group_id="O6" value="-3.53" spread="1.253"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
        <description>The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
        <time_frame>Baseline up to Day 17</time_frame>
        <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Negative Nasopharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
          <description>The time to negative nasopharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using nasopharyngeal sample. Time to negative nasopharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
          <population>Participants in the Nasopharyngeal mFAS with available data were analyzed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="10"/>
                <count group_id="O6" value="13"/>
                <count group_id="O7" value="46"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O2" value="17.0" lower_limit="16.0" upper_limit="17.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O4" value="16.0" lower_limit="7.0" upper_limit="16.0"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
        <description>The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
        <time_frame>Baseline up to Day 17</time_frame>
        <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Negative Oropharyngeal SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
          <description>The time to negative oropharyngeal SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using an oropharyngeal sample. Time to negative oropharyngeal SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
          <population>Participants in the Oropharyngeal mFAS with available data were analyzed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="9"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="11"/>
                <count group_id="O7" value="41"/>
                <count group_id="O8" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="4.0" upper_limit="16.0"/>
                    <measurement group_id="O3" value="13.0" lower_limit="7.0" upper_limit="NA">Due to smaller number of participants with an event, upper limit of 95% CI could not be calculated.</measurement>
                    <measurement group_id="O4" value="5.0" lower_limit="2.0" upper_limit="15.0"/>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O6" value="14.0" lower_limit="5.0" upper_limit="15.0"/>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
        <description>The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
        <time_frame>Baseline up to Day 17</time_frame>
        <population>Participants in the Saliva mFAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>RDV + Placebo, Part A</title>
            <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O3">
            <title>Placebo, Part A</title>
            <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>RDV, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>RDV + Placebo, Part B</title>
            <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
          </group>
          <group group_id="O6">
            <title>Placebo, Part B</title>
            <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Negative Saliva SARS-CoV-2 Polymerase Chain Reaction (PCR)</title>
          <description>The time to saliva SARS-CoV-2 PCR was defined as the number of days to first confirmed negative (first date of two consecutive dates achieving negative result) using saliva sample. Time to negative saliva SARS-CoV-2 PCR was calculated using Kaplan-Meier estimates.</description>
          <population>Participants in the Saliva mFAS with available data were analyzed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="10"/>
                <count group_id="O5" value="9"/>
                <count group_id="O6" value="12"/>
                <count group_id="O7" value="45"/>
                <count group_id="O8" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O2" value="17.0" lower_limit="13.0" upper_limit="17.0"/>
                    <measurement group_id="O3" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O4" value="16.0" lower_limit="7.0" upper_limit="16.0"/>
                    <measurement group_id="O5" value="14.0" lower_limit="3.0" upper_limit="15.0"/>
                    <measurement group_id="O6" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O7" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants had negative SARS-CoV-2 PCR result, the median time to negative SARS-CoV-2 PCR couldn't be calculated.</measurement>
                    <measurement group_id="O8" value="16.0" lower_limit="7.0" upper_limit="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C</title>
        <description>The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.</description>
        <time_frame>First dose date up to Day 14</time_frame>
        <population>Participants in FAS with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>RDV, Part C</title>
            <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Placebo, Part C</title>
            <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Alleviation (Mild or Absent) of Baseline COVID-19 Symptoms as Reported on the COVID-19 Adapted InFLUenza Patient-Reported Outcome (FLU-PRO©) Questionnaire in Part C</title>
          <description>The InFLUenza Patient-Reported Outcome (FLU-PRO©) is a 32-item patient-reported outcome questionnaire that assesses the severity of symptoms of influenza and influenza-like illness across six body systems. An additional two items can be added to assess changes in taste or smell, if the instrument is used to quantify symptoms in studies of COVID-19. Each domain scores ranges from 0 (symptom-free) to 4 (very severe symptoms). Higher scores on this scale represent higher disease severity. Alleviation is defined as symptom scores as 2 or higher at baseline are scored as 0 (absent) or 1 (mild) at post-baseline, and symptoms scored as 1 at baseline are scored as 0 at post-baseline, and for two consecutive days. Time to alleviation was calculated using Kaplan-Meier estimates.</description>
          <population>Participants in FAS with available data were analyzed.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants achieved alleviation, the median time to alleviation couldn't be calculated.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Since less than 50% of participants achieved alleviation, the median time to alleviation couldn't be calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events: First dose date up to 5 days plus 30 days All-Cause Mortality: Randomization date up to 35 days</time_frame>
      <desc>Adverse Events: The Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of study treatment.&#xD;
All-Cause Mortality: All Randomized Analysis Set included all participants who were randomized in the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>RDV, Part A</title>
          <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>RDV + Placebo, Part A</title>
          <description>Participants received inhaled RDV 31 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="E3">
          <title>Placebo, Part A</title>
          <description>Participants received placebo to match inhaled RDV in Part A daily for 5 days.</description>
        </group>
        <group group_id="E4">
          <title>RDV, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 5 days.</description>
        </group>
        <group group_id="E5">
          <title>RDV + Placebo, Part B</title>
          <description>Participants received inhaled RDV 62 mg administered daily as an aerosolized solution by inhalation through facemask for 3 days followed by placebo to match RDV daily for 2 days.</description>
        </group>
        <group group_id="E6">
          <title>Placebo, Part B</title>
          <description>Participants received placebo to match inhaled RDV in Part B daily for 5 days.</description>
        </group>
        <group group_id="E7">
          <title>RDV, Part C</title>
          <description>Participants received inhaled RDV 39 mg administered daily as an aerosolized solution by inhalation through mouth piece for 5 days.</description>
        </group>
        <group group_id="E8">
          <title>Placebo, Part C</title>
          <description>Participants received placebo to match inhaled RDV in Part C daily for 5 days.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="62"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Covid-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Lacrimation increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Otitis media viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Lymphocyte count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ageusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

